Terminal breast cancer patients have spoken of their distress after learning that a life-extending drug they had been told would be available to them looks set to be withdrawn.
Advisory body NICE is reviewing drugs made available through the old cancer drugs fund, and has rejected Kadcyla for use on the NHS in England.
It believes the price per patient set by manufacturer Roche is too expensive. Roche says discussions are continuing.
Read Full Article Here >>